BIOMARIN PHARMACEUTICAL INC Equity Securities, FV-NI, Realized Gain (Loss)
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Equity Securities, FV-NI, Realized Gain (Loss) of $714.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-27.
Discontinued › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiRealizedGainLoss · last filed 2020-02-27
- BIOMARIN PHARMACEUTICAL INC equity securities, fv-ni, realized gain (loss) for fiscal 2019 was $714.00K.
- BIOMARIN PHARMACEUTICAL INC equity securities, fv-ni, realized gain (loss) for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- BIOMARIN PHARMACEUTICAL INC equity securities, fv-ni, realized gain (loss) for fiscal 2017 was $3.25M.
- BIOMARIN PHARMACEUTICAL INC equity securities, fv-ni, realized gain (loss) for fiscal 2016 was -$108.00K.
| Period end | Equity Securities, FV-NI, Realized Gain (Loss) 12 month |
|---|---|
| 2019-12-31 | $714.00K 10-K · filed 2020-02-27 |
| 2018-12-31 | $0.00 10-K · filed 2020-02-27 |
| 2017-12-31 | $3.25M 10-K · filed 2020-02-27 |
| 2016-12-31 | -$108.00K 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |